BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37235572)

  • 1. Prevalence of psychological distress, quality of life, and satisfaction among patients and family members following comprehensive genomic profiling testing: Protocol of the Quality of life for Cancer genomics and Advanced Therapeutics (Q-CAT) study.
    Nishino M; Fujimori M; Koyama T; Hirata M; Tanabe N; Shimizu T; Yamamoto N; Uchitomi Y
    PLoS One; 2023; 18(5):e0283968. PubMed ID: 37235572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of psychological distress and associated factors among patients undergoing comprehensive genomic profiling testing: protocol for a multicentre, prospective, observational study.
    Matsuoka A; Fujimori M; Koyama T; Sato A; Mori K; Hirata M; Tanabe N; Nakachi K; Kato S; Okamoto H; Ogawa K; Komatsu H; Iwasaku M; Miyaji T; Uchitomi Y
    BMJ Open; 2023 Nov; 13(11):e072472. PubMed ID: 37996226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study.
    Best MC; Bartley N; Napier CE; Fisher A; Ballinger ML; Thomas DM; Goldstein D; Tucker K; Biesecker BB; Butow P
    Support Care Cancer; 2022 Oct; 30(10):8201-8210. PubMed ID: 35809119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan.
    Tang W; Hanada K; Motoo Y; Sakamaki H; Oda T; Furuta K; Abutani H; Ito S; Tsutani K
    J Med Econ; 2023; 26(1):614-626. PubMed ID: 37073487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
    Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
    J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychological impact of comprehensive tumor genomic profiling results for advanced cancer patients.
    Butow PN; Best MC; Davies G; Schlub T; Napier CE; Bartley N; Ballinger ML; Juraskova I; Meiser B; Goldstein D; Biesecker B; Thomas DM;
    Patient Educ Couns; 2022 Jul; 105(7):2206-2216. PubMed ID: 35153126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan.
    Kohno T; Kato M; Kohsaka S; Sudo T; Tamai I; Shiraishi Y; Okuma Y; Ogasawara D; Suzuki T; Yoshida T; Mano H
    Cancer Discov; 2022 Nov; 12(11):2509-2515. PubMed ID: 36321305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PiGeOn project: protocol for a longitudinal study examining psychosocial, behavioural and ethical issues and outcomes in cancer tumour genomic profiling.
    Best M; Newson AJ; Meiser B; Juraskova I; Goldstein D; Tucker K; Ballinger ML; Hess D; Schlub TE; Biesecker B; Vines R; Vines K; Thomas D; Young MA; Savard J; Jacobs C; Butow P
    BMC Cancer; 2018 Apr; 18(1):389. PubMed ID: 29621994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychological outcomes in advanced cancer patients after receiving genomic tumor profiling results.
    Vatter S; Schlub TE; Napier CE; Best MC; Bartley N; Juraskova I; Meiser B; Ballinger ML; Biesecker BB; Goldstein D; Thomas DM; Butow P;
    Health Psychol; 2022 Jun; 41(6):396-408. PubMed ID: 35604703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An approach for improvement of the accuracy of cancer gene panel testing.
    Imoto K; Yamamoto H; Ohkawa C; Shimada N; Ikuzawa R; Takeda H; Ohhara T; Kojima Y; Furuya N; Motoyoshi A; Migita O; Kuga A; Keira T; Wakamatsu H; Sato T; Oike N; Koike J; Yamano Y; Sunakawa Y
    Int J Clin Oncol; 2024 May; 29(5):571-581. PubMed ID: 38472663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Data-Sharing Systems of the Center for Cancer Genomics and Advanced Therapeutics(C-CAT)Repository Database and Expectation for the Future Medical Research and Development].
    Suzuki T
    Gan To Kagaku Ryoho; 2022 Nov; 49(11):1175-1182. PubMed ID: 36412016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer.
    Best M; Newson AJ; Meiser B; Juraskova I; Goldstein D; Tucker K; Ballinger ML; Hess D; Schlub TE; Biesecker B; Vines R; Vines K; Thomas D; Young MA; Savard J; Jacobs C; Butow P
    BMC Cancer; 2018 Apr; 18(1):454. PubMed ID: 29685123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive genomic profiling and treatment patterns across ancestries in advanced prostate cancer: a large-scale retrospective analysis.
    Sivakumar S; Lee JK; Moore JA; Hopkins J; Newberg JY; Madison R; Graf R; Schrock AB; Kobetz E; Vince R; Franco I; Seldon C; Frampton GM; Mills J; Venstrom J; Mahal BA
    Lancet Digit Health; 2023 Jun; 5(6):e380-e389. PubMed ID: 37236698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges of Conducting Value Assessment for Comprehensive Genomic Profiling.
    Tarride JE; Gould T; Thomas DM
    Int J Technol Assess Health Care; 2022 Jun; 38(1):e57. PubMed ID: 35674123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
    Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
    Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice.
    Čerina D; Matković V; Katić K; Lovasić IB; Šeparović R; Canjko I; Jakšić B; Fröbe A; Pleština S; Bajić Ž; Vrdoljak E
    Pathol Oncol Res; 2021; 27():1609963. PubMed ID: 34646088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current Status and Future Direction of Cancer Genomic Medicine in Japan].
    Muto M
    Gan To Kagaku Ryoho; 2020 Feb; 47(2):197-202. PubMed ID: 32381946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline sequencing for presumed germline pathogenic variants via tumor-only comprehensive genomic profiling.
    Kondo T; Yamamoto Y; Fukuyama K; Kanai M; Yamada A; Matsubara J; Quy PN; Yoshioka M; Yamada T; Minamiguchi S; Matsumoto S; Kosugi S; Muto M
    Int J Clin Oncol; 2022 Aug; 27(8):1256-1263. PubMed ID: 35567649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing Survival Outcomes for Advanced Cancer Patients Who Received Complex Genomic Profiling Using a Synthetic Control Arm.
    O'Haire S; Degeling K; Franchini F; Tran B; Luen SJ; Gaff C; Smith K; Fox S; Desai J; IJzerman M
    Target Oncol; 2022 Sep; 17(5):539-548. PubMed ID: 36063280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment and implementation of Cancer Genomic Medicine in Japan.
    Mukai Y; Ueno H
    Cancer Sci; 2021 Mar; 112(3):970-977. PubMed ID: 33289217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.